Vertex Reports Breakthrough Data for ALYFTREK in Young CF Patients — Vertex Pharmaceuticals Incorporated

Event summary

Vertex presented data showing ALYFTREK achieved sweat chloride <30 mmol/L in 65% of CF patients aged 2-5, surpassing prior treatments.
96-week interim analyses confirmed long-term safety and efficacy of ALYFTREK in patients aged 6+ and 12+.
Vertex plans global regulatory submissions for ALYFTREK in children 2-5 in H1 2026 and TRIKAFTA in children 1-<2.
Phase 3 data showed TRIKAFTA reduced sweat chloride by -71.8 mmol/L in children 12-<24 months.

The big picture

Vertex's data positions ALYFTREK as a potential game-changer in early CF intervention, addressing a critical unmet need in pediatric patients. The results reinforce Vertex's dominance in CFTR modulator development, while the planned regulatory submissions could significantly expand its addressable market. The focus on younger patients aligns with industry trends toward earlier disease modification in genetic disorders.

What we're watching

Regulatory Timing: Whether Vertex can secure approvals for ALYFTREK in younger patients by H1 2026 as planned.
Market Expansion: How quickly Vertex can expand ALYFTREK's use to broader CF patient populations.
Competitive Positioning: Whether these data solidify Vertex's leadership in CFTR modulator therapies.